Economic content in medical journal advertisements for medical devices and prescription drugs.
Previous studies of economic content in medical journal advertisements have not examined all types of economic content and have not included advertisements for medical devices. To examine trends in the economic content of medical device and pharmaceutical advertisements in medical journals. Three reviewers examined pharmaceutical and medical device advertisements in six leading medical journals from 1997 through 2006. Product characteristics, economic claims and evidence to support those claims were evaluated. Economic content appeared in 23.5% (561/2389) of pharmaceutical and device advertisements; 11.9% made market share claims and 12.7% made other economic claims. From 1997 through 2006, the percentage of medical device advertisements containing economic content declined from 26.7% to 6.7% (p = 0.02), whereas the percentage of pharmaceutical advertisements containing economic content remained stable (21.6-22.0%; p = 0.99). For pharmaceuticals, price claims declined significantly (15.7-4.2%; p < 0.01) and market share claims increased (2.8-11.5%; p = 0.09), and both consistently presented evidence (83% and 98%, respectively) while other types did not (e.g. 13.5% of formulary claims). Medical device economic claims differed from pharmaceutical economic claims; they made fewer market share claims (1.1% vs 12.8%) but more cost-effectiveness (6.5% vs 0.6%) and reimbursement (4.9% vs 0.8%) claims. Fewer than 2% of device advertisements with economic claims provided supporting evidence. The prevalence and type of economic content in pharmaceutical and device advertisements changed between 1997 and 2006, which may reflect evolving market dynamics, such as changes in reimbursement systems. Furthermore, the lack of supporting evidence in medical device advertisements and pharmaceutical formulary claims are potential areas of concern that require additional scrutiny by regulators and journal editors.
Ackerly
D Clay
DC
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA.
Glickman
Seth W
SW
Schulman
Kevin A
KA
D000329:Advertising / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data* / Q000639:trends; D017046:Cost Savings / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D004345:Drug Industry; D004864:Equipment and Supplies / Q000191:economics*; D019981:Health Care Sector; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000706:statistics & numerical data; D010506:Periodicals as Topic; D055553:Prescription Drugs / Q000191:economics*
D055553:Prescription Drugs
Health Aff (Millwood). 2008 Nov-Dec;27(6):1544-53
18997210
Health Res Policy Syst. 2005 Mar 17;3(1):4
15774017
Med Device Technol. 2006 May;17(4):26-8
16886819
Med Care. 2002 Sep;40(9):840-5
12218774
Health Aff (Millwood). 2000 Nov-Dec;19(6):266-76
11192413
Arch Intern Med. 2007 Apr 9;167(7):663-8
17420424
NHPF Issue Brief. 2002 Jun 7;(775):1-19
12083159
N Engl J Med. 2003 Dec 4;349(23):2224-32
14657430
J Manag Care Pharm. 2008 Oct;14(8):749-55
18983204
Biometrics. 1977 Mar;33(1):159-74
843571
PLoS Med. 2007 Sep;4(9):e283
17896856
JAMA. 2003 Aug 20;290(7):953-8
12928475